Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nam Seok Baek"'
Autor:
Myongjae Lee, Eunhye Jang, Jungwoo Lee, SungKu Choi, Won Sik Lee, Nam Seok Baek, Sungsook Lee, Young-Whan Park, Jong-Hwa Lee, Suk-Jae Chung
Publikováno v:
Journal of Analytical Science and Technology, Vol 14, Iss 1, Pp 1-13 (2023)
Abstract Venadaparib (VEN), a next-generation inhibitor of poly (ADP-ribose) polymerases, is under development for oral use in patients having cancers with deoxyribonucleic acid repair defects. The objective of this study was to develop and validate
Externí odkaz:
https://doaj.org/article/fd12115b3a8540f3bb8220e9adb6a776
Autor:
Myongjae Lee, In-Gyu Je, Jeong Eun Kim, Yeongran Yoo, Jong-Ha Lim, Eunhye Jang, Yoonsuk Lee, Dong Keun Song, An-Na Moon, Jeong-Ah Kim, Jinah Jeong, Joon-Tae Park, Jung Woo Lee, Ji-Hoon Yang, Chang-Hee Hong, Sun-Young Park, Young-Whan Park, Nam Seok Baek, Sungsook Lee, Kyoung Soo Ha, SungKu Choi, Won Sik Lee
Publikováno v:
Molecular Cancer Therapeutics. 22:333-342
PARP inhibitors have been approved by the FDA for use in the treatment of patients with ovarian, breast, pancreatic, and prostate cancers. PARP inhibitors show diverse suppressive effects on PARP family members and PARP-DNA trapping potency. These pr
Autor:
Won Sik Lee, SungKu Choi, Kyoung Soo Ha, Sungsook Lee, Nam Seok Baek, Young-Whan Park, Sun-Young Park, Chang-Hee Hong, Ji-Hoon Yang, Jung Woo Lee, Joon-Tae Park, Jinah Jeong, Jeong-Ah Kim, An-Na Moon, Dong Keun Song, Yoonsuk Lee, Eunhye Jang, Jong-Ha Lim, Yeongran Yoo, Jeong Eun Kim, In-Gyu Je, Myongjae Lee
Supplementary Table 1, Supplementary Table 2, Supplementary Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::658217c63256ede354d5c219e97c7ada
https://doi.org/10.1158/1535-7163.22523860.v1
https://doi.org/10.1158/1535-7163.22523860.v1
Autor:
Yong Man Kim, Kyun-Seop Bae, Eun-Jihn Roh, Kyungun Kim, Nam Seok Baek, Won Sik Lee, Sung-Bae Kim, Chan Young Ock
Publikováno v:
Journal of Clinical Oncology. 39:3107-3107
3107 Background: Poly ADP-ribose polymerase (PARP) is an enzyme that is central to the repair of DNA replication errors known as single-strand breaks (SSBs). PARP inhibitors are currently approved for ovary, breast, pancreatic and prostate cancers wh
Autor:
Jeong-Ah Kim, Lee Yoon-Suk, Dong-Gu Jeong, An-Na Moon, Sungsook Lee, In-Gyu Je, Soobong Park, Hun-Kyo Kim, Kim Kyung-Sun, Jeongcheol Shin, Myong-Jae Lee, Ji-Hoon Yang, Hong Sub Lee, Joon-Tae Park, Do-Hee Kim, Nam Seok Baek, Yong-Man Kim, Jung Yong Kim
Publikováno v:
Cancer Research. 78:4842-4842
Background PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. We aimed to develop a novel PARP in
Autor:
In-Gyu Je, Yong-Man Kim, Dong-Keun Song, Joon-Tae Park, Do-Hee Kim, Sungsook Lee, Lee Yoon-Suk, Jung Yong Kim, Hong Sub Lee, Dong Woo Kang, Shin-Wha Lee, Myong-Jae Lee, Jin-Ah Jeong, Nam Seok Baek, Jae-Hoon Kang, Ha Young Lee, Ji-hun Yang, Soobong Park
Publikováno v:
Molecular Cancer Therapeutics. 17:A106-A106
Background: PARP inhibitors have demonstrated clinically meaningful increase in progression-free survival as a single agent in women with recurrent ovarian cancer following a response to platinum-based chemotherapy. However, there still needs more im